NCT05206682 Comparison of the Therapeutic Effects of Vaginal Repair With Leuprorelin and Vaginal Repair in the Treatment of Cesarean Section Scar Defect
| NCT ID | NCT05206682 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Xinhua Hospital, Shanghai Jiao Tong University School of Medicine |
| Condition | Cesarean Section; Dehiscence |
| Study Type | INTERVENTIONAL |
| Enrollment | 94 participants |
| Start Date | 2023-05-01 |
| Primary Completion | 2027-04-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 94 participants in total. It began in 2023-05-01 with a primary completion date of 2027-04-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
GnRH-a will be used to postpone period after vaginal repair for Cesarean Section Scar Defect（CSD） patients with adenomyosis which will be compared with CSD patients with adenomyosis who receive transvaginal surgery without GnRH-a, whether delayed period improving the CSD prognosis will be assessed.
Eligibility Criteria
Inclusion Criteria: 1. Clearly diagnosed with CSD complicated with adenomyosis 2. Experiencing clinical features of abnormal uterine bleeding, prolonged menstrual flow (the duration of menstruation is more than 10 days). 3. The thickness of the remaining muscular layer of CSD was less than 3 mm. 4. Normal range of blood sugar and insulin 5. No serious medical problems (important viscera function in the normal range). 6. uterine fibroids no more than 5cm 7. Sign the informed consent. Exclusion Criteria: 1. Indefinite diagnosis. 2. Malignant tumors. 3. With severe medical problems (severe liver disease, kidney disease, respiratory diseases, heart disease or uncontrolled diabetes, epilepsy, etc., dysfunction of important organs). 4. Pregnant. 5. Mental diseases. 6. Allergy to the any ingredients of Leuprorelin 7. Unwilling to comply with the research plan.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT05206682 clinical trial?
This trial is open to female participants only, aged 18 Years or older, up to 50 Years, studying Cesarean Section; Dehiscence. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05206682 currently recruiting?
Yes, NCT05206682 is actively recruiting participants. Contact the research team at steveoizzie@icloud.com for enrollment information.
Where is the NCT05206682 trial being conducted?
This trial is being conducted at Shanghai, China.
Who is sponsoring the NCT05206682 clinical trial?
NCT05206682 is sponsored by Xinhua Hospital, Shanghai Jiao Tong University School of Medicine. The trial plans to enroll 94 participants.